头孢地尔药敏试验的考量:特洛伊木马之踵?
头孢地尔是一种新型铁载体偶联头孢菌素,对多重耐药需氧革兰阴性杆菌有活性。其体外药敏试验需考虑铁浓度:肉汤微量稀释法需使用铁耗竭CAMHB,纸片扩散法推荐标准MH琼脂。目前FDA和EUCAST已有解释折点,CLSI折点仍为研究用。
要点
- 肉汤微量稀释法需使用铁耗竭CAMHB以预测体内活性。
- 纸片扩散法推荐标准MH琼脂,因培养基中铁被结合。
- FDA或EUCAST折点应用于肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌复合群。
核心结论
- 头孢地尔对多重耐药需氧革兰阴性杆菌有活性,但药敏试验需考虑铁浓度。
- FDA和EUCAST折点可用于肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌复合群的临床解释。
研究设计与样本
- 本文为综述,汇总头孢地尔体外药敏试验方法及折点信息。
主要发现
- 头孢地尔通过铁载体组分利用主动铁转运进入细菌周质空间。
- 其头孢菌素部分结构类似头孢他啶与头孢吡肟的杂合体。
- 肉汤微量稀释法需铁耗竭CAMHB,纸片扩散法推荐标准MH琼脂。
- CLSI已描述铁耗竭CAMHB的制备方法。
关键数值与推荐
- FDA和EUCAST已有头孢地尔折点,CLSI折点为研究用。
- 对肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌复合群,应使用FDA或EUCAST折点解释结果。
- 对非鲍曼不动杆菌复合群和嗜麦芽窄食单胞菌的药敏试验应限于研究用途。
临床怎么用
- 临床解读头孢地尔药敏结果时,对肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌复合群应使用FDA或EUCAST折点。
- 肉汤微量稀释法需使用铁耗竭CAMHB,纸片扩散法使用标准MH琼脂。
- 对非鲍曼不动杆菌复合群和嗜麦芽窄食单胞菌的药敏试验应限于研究用途。
局限性
- 需进一步临床结局数据评估头孢地尔对非鲍曼不动杆菌复合群和嗜麦芽窄食单胞菌的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cefiderocol (formerly S-649266) is a novel siderophore-conjugated cephalosporin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram-negative bacilli. The siderophore component binds iron and uses active iron transport for drug entry into the bacterial periplasmic space. The cephalosporin moiety is the active antimicrobial component, structurally resembling a hybrid between ceftazidime and cefepime. Like other β-lactam agents, the principal bactericidal activity of cefiderocol occurs via inhibition of bacterial cell wall synthesis by binding of penicillin-binding proteins (PBPs) and inhibiting peptidoglycan synthesis, leading to cell death. Iron concentrations need to be taken into consideration when in vitro antimicrobial susceptibility to cefiderocol is determined. Broth microdilution (BMD) and disk diffusion methods have been developed to determine in vitro activity of cefiderocol. For BMD, cation-adjusted Mueller-Hinton broth (CAMHB) requires iron depletion to provide MICs predictive of in vivo activity. A method to prepare iron-depleted CAMHB (ID-CAMHB) has been described by the Clinical and Laboratory Standards Institute (CLSI). For disk diffusion, standard Mueller-Hinton agar is recommended, presumably because iron is bound in the medium. Currently, clinical FDA and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and investigational (research-use-only) CLSI breakpoints exist for interpreting cefiderocol susceptibility results for certain Gram-negative bacilli. Cefiderocol does not have clinically relevant activity against Gram-positive or anaerobic organisms. FDA or EUCAST breakpoints should be applied to interpret results for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex for patient care until the investigational status has been removed from CLSI breakpoints. Further clinical outcome data are required to assess the effectiveness of cefiderocol for treatment of other Acinetobacter species (non-baumannii complex) and Stenotrophomonas maltophilia at this time, and, as such, antimicrobial susceptibility testing of these organisms should be limited to research use in the scenario of limited treatment options.
引用
- Simner PJ, Patel R. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse? J Clin Microbiol. 2020. PMID: 32727829. doi:10.1128/JCM.00951-20
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。